Lakefront Biotherapeutics NV
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Feb 23, 2026 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 12, 2025 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 23, 2024 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 24, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Feb 23, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| operating cash outflow | Q1 2026 | 50 | New |
| one-time restructuring cash impact | 2026 | 125 to 175 | New |
| cash costs | 2026 | 35 to 40 | Lowered |
| Costs related to the ongoing TYK2 program | 2026 | 40 | Raised |
| cash and financial investments | December 31, 2026 | 2.775 to 2.85 | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Lakefront Biotherapeutics filed with the SEC
Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Lakefront Receives Transparency Notification from Bank of America
EX-99.1 to Form 6-K
Mechelen, Belgium; October 06, 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; 29 September 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; September 22, 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; 15 September 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; 08 September 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; 25 August 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Lakefront Receives Transparency Notification from Bank of America
EX-99.1 to Form 6-K
Mechelen, Belgium; 18 August 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Galapagos NV Half-Year Financial Report 2026
EX-99.2 to Form 6-K
Mechelen, Belgium; 04 August 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; July 28, 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; 07 July 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Lakefront Receives Transparency Notification from Madison Avenue Partners
EX-99.1 to Form 6-K
Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Mechelen, Belgium; June 16, 2026, 22.01 CET; regulated information
EX-99.1 to Form 6-K
Lakefront Announces Initiation of €50 Million Stock Repurchase Program
EX-99.1 to Form 6-K
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
EX-99.1 to Form 6-K
Lakefront Receives Transparency Notification from Bank of America
EX-99.1 to Form 6-K
Galapagos Announces Nomination of Gino Santini to its Board of Directors
EX-99.2 to Form 6-K
Galapagos Receives Transparency Notification from Bank of America
EX-99.1 to Form 6-K